Table 3.
Analysis of MDDC maturation after HIV inhibition by antibodies
|
% of CD83+ MDDCs
|
% of p24-positive MDDCs
|
||
|---|---|---|---|
| 24 h | 64 h | 64 h | |
| LPS, 10 μg/mL | 52 ± 3 | 70 ± 5 | — |
| Control uninfected iMDDCs | 2.0 ± 0.1 | 1.8 ± 0.4 | — |
| HIV-1BaL—infected MDDCs without Ig | 2.2 ± 0.2 | 2.2 ± 1.0 | 5.2 ± 0.2 |
| HIV-1BaL—infected MDDCs with neutralizing monoclonal IgG | |||
| 2F5, 5 μg/mL | 2.8 ± 0.4 | 2.7 ± 0.3 | 0.03 ± 0.01 |
| 2G12, 5 μg/mL | 3.0 ± 0.9 | 2.8 ± 0.4 | 0.2 ± 0.05 |
| 447-52D, 5 μg/mL | 2.8 ± 0.1 | 3.0 ± 0.1 | 0.2 ± 0.02 |
| 447-52D, 0.08 μg/mL | ND | 3.9 ± 1.0 | 1.9 ± 0.2 |
| HIV-1BaL—infected MDDCs with purified polyclonal Ig | |||
| IgG no. 11, 170 μg/mL | 4.0 ± 2.2 | 3.9 ± 2.2 | 0.4 ± 0.1 |
| IgG no. 11, 40 μg/mL | ND | 2.9 ± 2.0 | 2.5 ± 0.5 |
| IgG no. 44, 70 μg/mL | ND | 2.7 ± 1.7 | 0.07 ± 0.01 |
| IgG no. 44, 15 μg/mL | ND | 2.0 ± 1.6 | 2.1 ± 0.4 |
| IgG no. 8, 50 μg/mL | 3.0 ± 0.8 | 3.1 ± 1.5 | 0.06 ± 0.01 |
| IgG no. 8, 10 μg/mL | ND | 2.4 ± 0.5 | 2.6 ± 0.5 |
| IgG no. 8, 380 μg/mL | ND | 5.3 ± 0.4 | 0.3 ± 0.01 |
| F(ab′)2 no. 8, 180 μg/mL | 3.0 ± 0.1 | 2.4 ± 0.6 | 1.5 ± 0.4 |
Percentage of CD83+ MDDCs was measured at 24 and 64 hours after HIV-1BaL infection in the presence or in the absence of different concentrations of monoclonal or polyclonal antibodies. Values represent the mean ± SD of 2 wells from 1 representative experiment of 3 performed with cells from different healthy donors.
ND indicates not determined.